A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease

Parkinsonism and Related Disorders

Volumn 14, Issue 1, 2008, Pages 77-80

  Warren, L ^a   Gibson, R ^b   Ishihara, L ^c   Elango, R ^b   Xue, Z ^a   Akkari, A ^a   Ragone, L ^a   Pahwa, Rajesh ^d   Jankovic, Joseph ^e   Nance, Martha ^f   Freeman, Alan ^g   Watts, Ray L ^h   Hentati, F ⁱ  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f Struthers Parkinson's Center   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ Institut National de Neurologie Tunisia   (Tunisia)

Author keywords

Founder haplotype; G2019S; LRRK2; Parkinson's disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EUROPE; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; MUTATION RATE; PARKINSON DISEASE; POPULATION GENETICS; PRIORITY JOURNAL; TUNISIA; UNITED STATES;

ADULT; AGED; EUROPE; FEMALE; FOUNDER EFFECT; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MIDDLE EAST; MUTATION; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; TUNISIA; UNITED STATES;

EID: 38349189767     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2007.02.001     Document Type: Article

References (7)

1. Hughes A.J., Ben Shlomo Y., Daniel S.E., and Lees A.J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 42 6 (1992) 1142-1146
2. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der B.M., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 4 (2004) 595-600
3. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 4 (2004) 601-607
4. Ishihara L., Warren L., Gibson R., Amouri R., Lesage S., Durr A., et al. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch Neurol 63 9 (2006) 1250-1254
5. Zabetian C.P., Hutter C.M., Yearout D., Lopez A.N., Factor S.A., Griffith A., et al. LRRK2 G2019S in families with Parkinson's disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 79 4 (2006) 752-758
6. Genin E., Tullio-Pelet A., Begeot F., Lyonnet S., and Abel L. Estimating the age of rare disease mutations: the example of Triple-A syndrome. J Med Genet 41 6 (2004) 445-449
7. Abecasis G.R., Cherny S.S., Cookson W.O., and Cardon L.R. Merlin-rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 30 1 (2002) 97-101